Ivan Kairatov is a leading figure in the biopharmaceutical sector, renowned for his ability to navigate the complex intersection of high-tech innovation and clinical development. With a career rooted in deep-tier research and development, Kairatov has spent years dissecting how molecular dysfunctions manifest as debilitating physical symptoms. In this conversation, we explore a groundbreaking study published in Nature Communications by researchers from VIB and KU Leuven, which utilizes machine learning to overhaul our traditional understanding of Parkinson’s disease. By shifting the focus from a “one-size-fits-all” clinical definition to a data-driven molecular classification, Kairatov provides insights into how this new framework could finally unlock effective, personalized therapies for millions of patients.
The following discussion examines the transition from symptom-based diagnosis to molecular subtyping, the role of artificial intelligence in identifying “natural clusters” within genetic data, and the future of precision medicine in neurology.
Parkinson’s patients often share similar clinical symptoms like movement issues, yet they differ significantly at the molecular level. How do the two main groups and five subgroups identified change our understanding of why a single drug often fails, and what specific molecular differences should researchers focus on next?
For decades, the medical community has viewed Parkinson’s through a narrow lens, focusing primarily on the outward clinical “unified” symptoms like tremors or rigidity. However, this study confirms what many researchers have long suspected: when you look “under the hood,” the biological reality is far more fragmented. By identifying two broad groups and five distinct molecular subgroups, we finally have a map that explains why a drug targeting one pathway might be a miracle for one patient but completely useless for another. This realization is profound because it suggests that a single, universal cure for Parkinson’s likely doesn’t exist. Instead, we must pivot our focus toward the specific dysfunctions associated with the 24 different genes known to cause the disease, as these genetic variations create entirely different cellular environments that require unique chemical interventions.
Studying 24 different genetic mutations in animal models allows for long-term behavioral monitoring. What specific patterns did the machine learning algorithms detect over time that humans might miss, and how did this lead to the discovery of natural clusters rather than traditional categories?
Humans are naturally biased; we tend to look for patterns that confirm our existing theories, which can often blind us to the subtle nuances of disease progression. In this research, the team used fruit fly models to monitor behavioral changes over extended periods, allowing machine learning algorithms to process vast amounts of raw data without any “preconceived notions.” These algorithms were able to detect minute variations in movement and activity levels that would be invisible to a human observer watching a screen. By letting the data guide the analysis, the AI uncovered “natural clusters” based on actual biological behavior rather than the rigid, traditional categories we’ve forced upon the disease for a century. This unbiased framework revealed a hidden structure within the 24 genetic mutations, proving that the disease organizes itself into subtypes that we are only just beginning to name and understand.
During testing, a compound that cured one subgroup failed to rescue another. Could you walk us through the step-by-step process of how these subgroup-specific responses were measured and what this implies for the design of future clinical trials involving human biomarkers?
The testing phase provided a stark, sensory realization of the necessity for precision medicine: the researchers identified a compound that successfully “rescued” the phenotype—essentially curing the symptoms—in subgroup A, but when that same compound was applied to subgroup B, it had absolutely no effect. This process involved a meticulous, step-by-step behavioral screening where the flies’ responses to various chemical compounds were measured against their specific genetic profiles. Seeing a treatment succeed in one group and fail in another within the same laboratory setting is a powerful signal that our future clinical trials must be far more selective. Instead of recruiting a broad pool of “Parkinson’s patients,” we need to use specific biomarkers to identify which molecular subgroup a patient belongs to before they ever receive a dose of an experimental drug. This shift will likely reduce trial failure rates and ensure that the right medicine reaches the right person at the right time.
This unbiased, data-driven framework could potentially be applied to other conditions caused by multiple genetic or environmental factors. Which specific diseases are most ripe for this type of classification, and what metrics would define success when moving this methodology from the lab to the clinic?
The principles established in this Parkinson’s study are incredibly versatile and could be a game-changer for any condition defined by high biological diversity, such as Alzheimer’s or even systemic conditions like Sjögren disease. Any ailment where a variety of different genes or environmental triggers lead to a similar clinical outcome is a prime candidate for this type of unbiased machine learning classification. When we move this from fruit fly models to human clinics, the primary metric of success will be the “rescue rate” of specific patient cohorts—essentially, how accurately we can predict a patient’s response to a drug based on their molecular subtype. If we can reach a point where we no longer see the 50% or 60% non-responder rates common in current trials, we will know that this data-driven framework has successfully bridged the gap between the lab and the bedside.
What is your forecast for Parkinson’s disease research?
I believe we are entering an era of “Personalized Parkinsonology,” where the diagnosis of the disease will soon be followed by a deep genetic and molecular sequencing to determine which of the five subgroups a patient fits into. Within the next decade, we will likely stop talking about Parkinson’s as a single entity and instead treat it as a collection of related but distinct conditions, much like we have done with various types of cancer. This will lead to a surge in “orphan drug” style developments, where smaller, more targeted clinical trials yield higher success rates because they are treating a biologically homogenous group. It is an incredibly hopeful time, as the integration of AI and molecular biology is finally giving us the tools to dismantle the complexity of the human brain and provide real, tailored relief to millions of people worldwide.
